Treatment of multiple myeloma and the role of melphalan in the era of modern therapies—Current research and clinical approaches
Multiple myeloma (MM) accounts for 10% of all hematological malignancies, and it is the
second most common hematological neoplasm for which chemotherapy is an important …
second most common hematological neoplasm for which chemotherapy is an important …
Aclarubicin-induced ROS generation and collapse of mitochondrial membrane potential in human cancer cell lines
A Rogalska, A Koceva-Chyła, Z Jóźwiak - Chemico-biological interactions, 2008 - Elsevier
The cytotoxicity of aclarubicin (ACL) in A549 (human non-small lung), HepG2 (human
hepatoma) and MCF-7 (human breast adenocarcinoma) cancer cell lines was evaluated and …
hepatoma) and MCF-7 (human breast adenocarcinoma) cancer cell lines was evaluated and …
Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer
…, A Gajek, A Marczak, A Rogalska - Journal of hematology & …, 2020 - Springer
Ovarian cancer is one of the most lethal gynecologic malignancies reported throughout the
world. The initial, standard-of-care, adjuvant chemotherapy in epithelial ovarian cancer is …
world. The initial, standard-of-care, adjuvant chemotherapy in epithelial ovarian cancer is …
[HTML][HTML] PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway
Ł Biegała, A Gajek, A Marczak, A Rogalska - Biochimica et Biophysica Acta …, 2021 - Elsevier
Ovarian cancer (OC) constitutes the most common cause of gynecologic cancer-related death
in women worldwide. Despite consistent developments in treatment strategies for OC, the …
in women worldwide. Despite consistent developments in treatment strategies for OC, the …
Induction of apoptosis in human ovarian cancer cells by new anticancer compounds, epothilone A and B
Epothilones are a new group of compounds with action mechanisms similar to taxanes. The
aim of this study was to compare the effects of epothilone A (Epo A) and epothilone B (Epo B…
aim of this study was to compare the effects of epothilone A (Epo A) and epothilone B (Epo B…
Gliclazide may have an antiapoptotic effect related to its antioxidant properties in human normal and cancer cells
A Sliwinska, A Rogalska, M Szwed, J Kasznicki… - Molecular Biology …, 2012 - Springer
Experimental and clinical studies suggest that gliclazide may protect pancreatic β-cells from
apoptosis induced by an oxidative stress. However, the precise mechanism(s) of this action …
apoptosis induced by an oxidative stress. However, the precise mechanism(s) of this action …
Olaparib-Resistant BRCA2MUT Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR …
Ł Biegała, A Gajek, A Marczak, A Rogalska - Cells, 2023 - mdpi.com
The PARP inhibitor (PARPi) olaparib is currently the drug of choice for serous ovarian
cancer (OC), especially in patients with homologous recombination (HR) repair deficiency …
cancer (OC), especially in patients with homologous recombination (HR) repair deficiency …
Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2MUT ovarian …
…, A Marczak, A Śliwińska, A Rogalska - Scientific Reports, 2023 - nature.com
Olaparib is a PARP inhibitor (PARPi) approved for targeted treatment of ovarian cancer (OC).
However, its efficacy is impeded by the inevitable occurrence of resistance. Here, we …
However, its efficacy is impeded by the inevitable occurrence of resistance. Here, we …
[HTML][HTML] Targeted nanocarrier-based drug delivery strategies for improving the therapeutic efficacy of PARP inhibitors against ovarian cancer
…, A Gajek, A Marczak, A Rogalska - International Journal of …, 2024 - mdpi.com
The current focus of ovarian cancer (OC) research is the improvement of treatment options
through maximising drug effectiveness. OC remains the fifth leading cause of cancer-induced …
through maximising drug effectiveness. OC remains the fifth leading cause of cancer-induced …
PARP inhibition increases the reliance on ATR/CHK1 checkpoint signaling leading to synthetic lethality—an alternative treatment strategy for epithelial ovarian cancer …
…, J Ostrowski, A Śliwińska, A Rogalska - International journal of …, 2020 - mdpi.com
Poly (ADP-ribose) polymerase inhibitor (PARPi, olaparib) impairs the repair of DNA single-strand
breaks (SSBs), resulting in double-strand breaks (DSBs) that cannot be repaired …
breaks (SSBs), resulting in double-strand breaks (DSBs) that cannot be repaired …